Merritt J E, Moores K E, Evans A T, Sharma P, Evans F J, MacPhee C H
SmithKline Beecham Pharmaceuticals Ltd., The Frythe, Welwyn, Herts, U.K.
Biochem J. 1993 Feb 1;289 ( Pt 3)(Pt 3):919-26. doi: 10.1042/bj2890919.
In this study, the effects of a series of phorbol esters with different spectra of biological activities and different patterns of activation of the isoenzymes of protein kinase C (PKC) have been studied in human neutrophils. The aim was to gain more information on which isoenzymes of PKC are involved in neutrophil activation, specifically inhibition of fMet-Leu-Phe (fMLP)-stimulated bivalent cation influx and stimulation of O2-. release (either alone or potentiation of the response to fMLP). Prior addition of both phorbol 12-myristate 13-acetate (PMA) and sapintoxin A (SAPA) inhibited fMLP-stimulated Mn2+ influx. Higher concentrations of resiniferatoxin (RX) were also inhibitory, inhibition being more apparent at longer preincubation times. However, 12-deoxyphorbol 13-O-phenylacetate (DOPPA) showed only a slight inhibitory effect and required a prolonged preincubation. PMA, SAPA and RX, but not DOPPA, stimulated O2-. release by themselves. Lower concentrations of PMA, SAPA and RX, which were ineffective alone, considerably potentiated O2-. release stimulated by fMLP, whereas DOPPA had little or no effect. These results rule out a major role for PKC-delta (not activated by SAPA) and PKC-beta 1 (activated by DOPPA), but suggest the involvement of RX kinase in addition to PKC in the inhibition of fMLP-stimulated Mn2+ influx and potentiation of fMLP-stimulated O2-. release. However, when the cytosolic free Ca2+ concentration ([Ca2+]i) was elevated with the Ca2+ ionophore ionomycin, DOPPA was able to stimulate O2-. release, which probably reflects the known Ca2+ requirement for activation of PKC-beta 1 by DOPPA in vitro. The effects of the other phorbols were also enhanced when [Ca2+]i was elevated; all of the phorbols synergize, to variable extents, with Ca2+ to activate PKC in vitro. Enhancement of RX-stimulated O2- release by elevation of [Ca2+]i was unexpected, since RX kinase has been reported to be inhibited by high concentrations of Ca2+ in vitro. Finally, use of fura-2 and SK&F 96365 to manipulate the fMLP-stimulated rise in [Ca2+]i showed that when fMLP was able to evoke its normal rise in [Ca2+]i (to a peak of 700-900 nM), O2-. release was potentiated by PMA, SAPA and RX. However, when fMLP was only able to evoke a small increase in [Ca2+]i (to a peak of 400 nM), potentiation by PMA was unaffected but potentiation by SAPA and RX was considerably reduced. This observation agrees with published data demonstrating that activation of PKC in vitro by SAPA is more Ca(2+)-dependent than activation by PMA.(ABSTRACT TRUNCATED AT 400 WORDS)
在本研究中,我们研究了一系列具有不同生物活性谱和不同蛋白激酶C(PKC)同工酶激活模式的佛波酯对人中性粒细胞的影响。目的是获取更多关于哪些PKC同工酶参与中性粒细胞激活的信息,特别是抑制甲酰甲硫氨酰-亮氨酰-苯丙氨酸(fMet-Leu-Phe,fMLP)刺激的二价阳离子内流以及刺激超氧阴离子(O2-)释放(单独或增强对fMLP的反应)。预先添加佛波醇12-肉豆蔻酸酯13-乙酸酯(PMA)和沙平毒素A(SAPA)均可抑制fMLP刺激的锰离子(Mn2+)内流。更高浓度的树脂毒素(RX)也具有抑制作用,在更长的预孵育时间下抑制作用更明显。然而,12-脱氧佛波醇13-O-苯乙酸酯(DOPPA)仅表现出轻微的抑制作用,且需要延长预孵育时间。PMA、SAPA和RX自身可刺激O2-释放,但DOPPA无此作用。单独无效的较低浓度的PMA S、APA和RX可显著增强fMLP刺激的O2-释放,而DOPPA几乎没有影响。这些结果排除了PKC-δ(不被SAPA激活)和PKC-β1(被DOPPA激活)的主要作用,但表明除PKC外,RX激酶也参与抑制fMLP刺激的Mn2+内流和增强fMLP刺激的O2-释放。然而,当用钙离子载体离子霉素升高胞质游离钙离子浓度([Ca2+]i)时,DOPPA能够刺激O2-释放,这可能反映了体外已知的DOPPA激活PKC-β1对钙离子的需求。当[Ca2+]i升高时,其他佛波酯的作用也增强;所有佛波酯在体外均与钙离子不同程度地协同激活PKC。[Ca2+]i升高增强RX刺激的O2-释放出乎意料,因为据报道RX激酶在体外被高浓度钙离子抑制。最后,使用fura-2和SK&F 96365来控制fMLP刺激的[Ca2+]i升高表明,当fMLP能够引起其正常的[Ca2+]i升高(峰值达到700-900 nM)时,PMA、SAPA和RX可增强O2-释放。然而,当fMLP仅能引起[Ca2+]i的小幅升高(峰值为400 nM)时,PMA的增强作用不受影响,但SAPA和RX的增强作用显著降低。这一观察结果与已发表的数据一致,表明体外SAPA激活PKC比PMA更依赖钙离子。(摘要截短于400字)